Agonistic analog of growth hormone–releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke

Yueyang Liu,Jingyu Yang,Xiaohang Che,Jianhua Huang,Xianyang Zhang,Xiaoxiao Fu,Jialing Cai,Yang Yao,Haotian Zhang,Ruiping Cai,Xiaomin Su,Qian Xu,Fu Ren,Renzhi Cai,Andrew V. Schally,Ming-Sheng Zhou

DOI: https://doi.org/10.1073/pnas.2109600118

IF: 11.1

2021-11-15

Proceedings of the National Academy of Sciences

Abstract:Significance Stroke is a leading cause of mortality and permanent disability in adults worldwide. Although most pharmacological neuroprotectants have beneficial effects in experimental studies, they fail in clinical trials. Here, we report that MR-409, a synthetic analog of growth hormone–releasing hormone, can reduce mortality and improve neurological functional recovery in mice operated on for tMCAO. Mechanistically, MR-409 stimulates endogenous neurogenesis and improves tMCAO-induced loss of neuroplasticity by activation of AKT/CREB and BDNF/TrkB pathways. Our preclinical studies support the notion that MR-409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis and may represent a potential new therapy for cerebral ischemic stroke.

multidisciplinary sciences